The first part of this two-part series by Ewan Bennett discussed the challenges surrounding funding for orphan drugs, specifically for health technology assessment (HTA). This second article examines what manufacturers should consider, after successfully overcoming any HTA hurdles, to achieve market access.
Read Ewan Bennett's full article in Pharmaphorum.
We are part of Decision Resources Group (DRG), a subsidiary of Piramal Enterprises Ltd.
DRG offers best-in-class, high-value data, analytics and insights products and services to the healthcare industry, delivered by more than 1,000 employees across 17 offices in North America, Europe and Asia.Our Company